Refill rates and budget impact of glaucoma lipid therapy: A retrospective database analysis

Clinical Drug Investigation

Volumn 27, Issue 12, 2007, Pages 819-825

  Walt, John G ^a   Wilensky, Jacob T ^b   Fiscella, Richard ^b   Chiang, Tina H ^a   Guckian, Angela ^c  

^a ALLERGAN INC   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c Wolters Kluwer Health   (United States)

Author keywords

Antiglaucomas, therapeutic use; Bimatoprost, therapeutic use; Cost analysis; Cost effectiveness; Glaucoma; Latanoprost, therapeutic use; Travoprost, therapeutic use

Indexed keywords

BIMATOPROST; LATANOPROST; TRAVOPROST;

ADOLESCENT; ADULT; AGED; ARTICLE; BUDGET; CHILD; CONTROLLED STUDY; DATA BASE; DRUG COST; FEMALE; GLAUCOMA; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE;

EID: 36349004656     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-200727120-00003     Document Type: Article

References (25)

1. Weinreb RN, Khaw PT. Primary open-angle glaucoma. Lancet 2004; 363: 1711-20
2. Distelhorst JS, Hughes GM. Open-angle glaucoma. Am Fam Phys 2003; 67: 1937-44, 1950
3. Dalzell MD. Glaucoma: prevalence, utilization, and economic implications. Pharmacy Thera 2002; 27 (11 Suppl.): 10-5
4. Kobelt-Nguyen G, Gerdtham UG, Alm A. Costs of treating primary open-angle glaucoma and ocular hypertension: a retrospective, observational two-year chart review of newly diagnosed patients in Sweden and the United States. J Glaucoma 1998; 7: 95-104
5. Mansukani SS. Glaucoma arrives on managed care's doorstep. Pharmacy Thera 2002; 27 (11 Suppl.): 6-9
6. Kass MA, Heuer SK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study. A randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol 2002; 120: 701-13
7. Kymes SM, Kass MA, Anderson DR, et al. Management of ocular hypertension: a cost-effectiveness approach from the Ocular Hypertension Treatment Study. Am J Ophthalmol 2006; 141 (6): 997-1008
8. American Academy of Ophthalmology. Primary open-angle glaucoma, preferred practice pattern [online]. San Francisco: American Academy of Ophthalmology, 2005. Available from URL: http://www.aao.org/ppp [Accessed 2007 Jun 18]
9. Schwartz K, Budenz D. Current management of glaucoma. Curr Opin Ophthalmol 2004; 15: 119-26
10. Goldberg I, Anton A, Skuta GL. Controversies in ophthalmology: should beta blockers be abandoned as initial monotherapy in chronic open-angle glaucoma? The controversy. Br J Ophthalmol 2002; 86: 691-5
11. Cantor L. Achieving low target pressures with today's glaucoma medications. Surv Ophthalmol 2003; 48 Suppl. 1: S8-S16
12. Xalatan® United States prescribing information [online]. Available from URL: http://www.pfizer.com/download/uspi_xalatan. pdf [Accessed 2007 Jun 18]
13. Travatan® United States prescribing information [online]. Available from URL: http://a1020.g.akamai.net/7/1020/2226/66c99f43327aaf/ecatalog.alcon. com/pi/travatan_us_en.pdf [Accessed 2007 Jun 18]
14. Lumigan® United States prescribing information [online]. Available from URL: http://www.lumigan.com/Media/pi.pdf [Accessed 2007 Jun 18]
15. Gandolfi S, Simmons R, Sturm K, et al. Three-month comparison of bimatoprost and latanoprost in patients with glaucoma and ocular hypertension. Adv Ther 2001; 18: 110-21
16. DuBiner H, Cooke D, Dirks M, et al. Efficacy and safety of bimatoprost in patients with elevated intraocular pressure: a 30-day comparison with latanoprost. Surv Ophthalmol 2001; 45 Suppl. 4: S353-60
17. Parrish RK, Palmberg P, Sheu W-P, et al. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week, randomized, masked-evaluator multicenter study. Am J Ophthalmol 2003; 135: 688-703
18. Noecker RS, Dirks MS, Choplin NT, et al. A six-month randomized clinical trial comparing the intraocular pressure-lowering efficacy of bimatoprost and latanoprost in patients with ocular hypertension or glaucoma. Am J Ophthalmol 2003; 135: 55-63
19. Walters TR, DuBiner HB, Carpenter SP, et al. 24-hour IOP control with once-daily bimatoprost, timolol gel-forming solution, or latanoprost: a 1-month, randomized, comparative clinical trial. Surv Ophthalmol 2004; 49 Suppl. 1: S26-35
20. The Eye Diseases Prevalence Research Group. Prevalence of open-angle glaucoma among adults in the United States. Arch Ophthalmol 2004; 122: 532-8
21. Law SK, Song BJ, Fang E, et al. Feasibility and efficacy of a mass switch from latanoprost to bimatoprost in glaucoma patients in a prepaid health maintenance organization. Ophthalmology 2005; 112: 2123-30
22. Mick AB, Gonzalez S, Dunbar MT, et al. A cost analysis of the prostaglandin analogs. Optometry 2002; 73: 614-9
23. Fiscella R, Wilensky JT, Chiang TH, et al. Efficiency of instillation methods for prostaglandin medications. J Ocul Pharmacol Ther 2006; 22: 477-82
24. Noecker RJ, Walt JG. Cost-effectiveness of monotherapy treatment of glaucoma and ocular hypertension with the lipid class of medications. Am J Ophthalmol 2006; 141: S15-21
25. Wilensky J, Fiscella RG, Carlson AM, et al. Measurement of persistence and adherence to regimens of IOP-lowering glaucoma medications using pharmacy claims data. Am J Ophthalmol 2006; 141: S28-33